Promising Study Reveals Cardiol Therapeutics' Subcutaneous Cannabidiol's Potential in Heart Failure Treatment| David Elsley, CEO, Cardiol Therapeutics Inc. 00:10:00
Groundbreaking research unveils the potential of subcutaneously administered cannabidiol in treating heart failure with preserved ejection fraction, showcasing promising results in curbing body and heart weight increase and preventing cardiac inflammatory markers' escalation. This study, conducted in a meticulously crafted pre-clinical model, underscores the significance of Cardiol Therapeutics' innovative approach in combating this debilitating condition, offering hope for effective treatment.
